Recipharm publishes prospectus

Not for release, publication or distribution, directly or indirectly, in or into
the United States, Canada, Australia, Japan, Hong Kong, New Zealand, South
Africa or any other jurisdiction where such distribution of this press release
would be subject to legal restrictions.
The prospectus relating to Recipharm rights issue in the amount of approximately
SEK 805 million has been approved and registered by the Swedish Financial
Supervisory Authority and is now available on the Company’s website
www.recipharm.com. The prospectus and the application forms will be sent by mail
to directly registered shareholders of Recipharm.

The prospectus and the application forms can be obtained from Recipharm,
Handelsbanken and Swedbank. The prospectus and the application forms will also
be available on Recipharm’s website www.recipharm.com/sv/investor
-relations/nyemission-2016, on DNB Markets’ website
www.dnb.no/emisjoner, on Handelsbanken’s website www.handelsbanken.se/
investerings-erbjudande (only in Swedish) and on Swedbank’s website,
www.swedbank.se/prospekt (only in Swedish).

DNB Markets, Handelsbanken Capital Markets and Swedbank Corporate Finance are
acting as financial advisors and Setterwalls Advokatbyrå as legal advisor to
Recipharm in connection with the rights issue.

Recipharm AB (publ)
The Board of Directors

For further information please visit www.recipharm.com or contact:
Thomas Eldered, CEO, +46 8 602 52 10
Björn Westberg, CFO, ir@recipharm.com, +46 8 602 46 20

This information is published in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the regulations of
Nasdaq Stockholm. This information was submitted for publication on 19 May 2016,
at 23:30hrs CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry employing some 3,200 employees.
Recipharm offers manufacturing services of pharmaceuticals in various dosage
forms, production of clinical trial material and APIs, and pharmaceutical
product development. Recipharm manufactures several hundred different products
to customers ranging from Big Pharma to smaller research- and development
companies. Recipharm’s turnover is approximately SEK 4.6 billion and the Company
operates development and manufacturing facilities in France, Germany, India,
Israel, Italy, Portugal, Spain, Sweden and the UK and is headquartered in
Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit
www.recipharm.com

Important information
The information in this press release does not constitute an offer to acquire,
subscribe for or otherwise trade in shares, subscription rights or other
securities in Recipharm. Any invitation to the persons concerned to subscribe
for shares in Recipharm will only be made through the prospectus that Recipharm
estimates to publish on or around 19 May 2016.

This press release may not be released, published or distributed, directly or
indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan,
New Zealand, South Africa or any other jurisdiction where such action is wholly
or partially subject to legal restrictions or where such action would require
additional prospectuses, registrations or other actions in addition to what
follows from Swedish law. Nor may the information in this press release be
forwarded, reproduced or disclosed in a manner that contravenes such
restrictions or would entail such requirements. Failure to comply with this
instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares have or will be
registered under the U.S. Securities Act of 1933, as amended, (“Securities
Act”), or securities legislation in any state or other jurisdiction in the
United States and may not be offered or sold, directly or indirectly, in or into
the United States, except pursuant to an available exemption from the
registration requirements of the Securities Act and in compliance with the
securities laws of any state or other jurisdiction of the United States.

This press release may contain forward-looking statements which reflect
Recipharm’s current view on future events and financial and operational
development. The words “intend”, “estimate”, “expect”, “may”, “plan”,
“anticipate” or similar expressions regarding indications or prognoses of future
developments or trends and which are not statements based on historical facts
constitute forward-looking information. Although Recipharm believes that these
statements are based on reasonable assumptions and expectations, Recipharm
cannot give any assurances that such statements will materialize. Forward
-looking statements are in its nature involved with both known and unknown risks
and uncertainties, since it is depending on future events and circumstances.
Forward-looking statements do not constitute any representations and warranties
and the outcome could differ materially from the information set out in the
forward-looking statements.
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
00, Fax 46 8 81 87 03
www.recipharm.com